Ny artikkel i VG
Publisert på VG.no i kveld:
https://www.vg.no/nyheter/innenriks/i/G3Peym/utvikler-ny-norsk-medisin-kan-bli-gjennombrudd-i-kamp-mot-infeksjoner
God PR 😀
https://www.vg.no/nyheter/innenriks/i/G3Peym/utvikler-ny-norsk-medisin-kan-bli-gjennombrudd-i-kamp-mot-infeksjoner
God PR 😀
Redigert 18.08.2021 kl 23:05
Du må logge inn for å svare
Gullhaugen
02.04.2025 kl 14:40
6801
den perfekte storm
https://www.globenewswire.com/en/news-release/2023/07/12/2703710/0/en/Penicillin-Drug-Market-to-reach-12-1-Billion-globally-by-2032-at-3-7-CAGR-Allied-Market-Research.html?utm_source=chatgpt.com
Det globale markedet for penicillin er betydelig og forventes å vokse i årene som kommer. Ifølge en rapport fra Allied Market Research, var markedet verdt 8,4 milliarder dollar i 2022 og forventes å nå 12,1 milliarder dollar innen 2032, med en årlig vekst på 3,7 % fra 2023 til 2032.
GlobeNewswire
En annen analyse indikerer at penicillinmarkedet vil vokse fra 10,38 milliarder dollar i 2023 til 12,16 milliarder dollar innen 2028, med en årlig vekst på 3,21 % i perioden 2023–2028.
stringentdatalytics.com
Disse estimatene reflekterer en stabil vekst i etterspørselen etter penicillin, drevet av økt bevissthet om kombinasjonsbehandlinger, høyere forekomst av bakterielle infeksjoner og tilgjengeligheten av generiske legemidler. Imidlertid kan utfordringer som antibiotikaresistens påvirke markedets utvikling i fremtiden.
https://www.globenewswire.com/en/news-release/2023/07/12/2703710/0/en/Penicillin-Drug-Market-to-reach-12-1-Billion-globally-by-2032-at-3-7-CAGR-Allied-Market-Research.html?utm_source=chatgpt.com
Det globale markedet for penicillin er betydelig og forventes å vokse i årene som kommer. Ifølge en rapport fra Allied Market Research, var markedet verdt 8,4 milliarder dollar i 2022 og forventes å nå 12,1 milliarder dollar innen 2032, med en årlig vekst på 3,7 % fra 2023 til 2032.
GlobeNewswire
En annen analyse indikerer at penicillinmarkedet vil vokse fra 10,38 milliarder dollar i 2023 til 12,16 milliarder dollar innen 2028, med en årlig vekst på 3,21 % i perioden 2023–2028.
stringentdatalytics.com
Disse estimatene reflekterer en stabil vekst i etterspørselen etter penicillin, drevet av økt bevissthet om kombinasjonsbehandlinger, høyere forekomst av bakterielle infeksjoner og tilgjengeligheten av generiske legemidler. Imidlertid kan utfordringer som antibiotikaresistens påvirke markedets utvikling i fremtiden.
Gullhaugen
02.04.2025 kl 15:12
6736
This stock will soon make you richer than you ever dreamed
Next steps for SBE-01
Having demonstrated early proof-of-concept for the SBE project and in accordance with the company's corporate strategy, SoftOx will seek a strategic partner to further develop and advance its wound care segment within acute and chronic indications.
Next steps for SBE-01
Having demonstrated early proof-of-concept for the SBE project and in accordance with the company's corporate strategy, SoftOx will seek a strategic partner to further develop and advance its wound care segment within acute and chronic indications.
Gullhaugen
07.04.2025 kl 08:53
6031
Hot er helt riktig.
TOP50 , det holdes på aksjene etter at flere har økt kraftig siste uken. The potential is so huge, no one above and no one next to it. Stay tuned because big things are happening soon 《 Proof of consept》. Almås øker ikke med 115 millioner aksjer på gøy.
Oversikt for SOFTX (SOFTOX SOLUTIONS ). Oppdatert VPS 7.04.2025
01 PRO AS 13.61% 11.52m 265.6m
02 ALMHAUG BOLIG AS 9.95% 8 426.1k 194.2m
03 OSLO NÆRINGSUTVIKLING AS 8.13% 6 886.2k 158.7m
04 J G INVEST AS 4.84% 4 098.2k 94.43m
05 HAREFRØKEN INVEST AS 4.80% 4 063.5k 93.63m
06 BONICA AS 4.37% 3 696.7k 85.18m
07 NORDNET LIVSFORSIKRING AS 2.87% 2 432.3k 56.04m -565.2k
08 DANSKE BANK A/S 2.54% 2 150.4k 49.55m
09 STIFTELSEN UNI 2.44% 2 068.2k 47.66m
10 LOYD AS 2.12% 1 792.5k 41.3m
11 NORDNET BANK AB 1.97% 1 668.6k 38.45m ++++1 226k
12 AUBERT INVEST AS 1.89% 1 604.3k 36.97m
13 ALMÅS INGEBORG VICTORIA AARSVOLD 1.83% 1 549.2k 35.7m
14 WL-02 HOLDING AS 1.57% 1 330.5k 30.66m
15 HOLTA & CO. AS 1.45% 1 224.4k 28.21m
16 GH HOLDING AS 1.30% 1 099k 25.32m
17 GEMALLO AS 1.28% 1 084.3k 24.98m
18 ARJO BYGG AS 0.90% 759.5k 17.5m
19 BØRSELIEN MARIUS 0.89% 752.02k 17.33m
20 THE BANK OF NEW YORK MELLON SA/NV 0.85% 716.79k 16.52m
21 RONGVED PÅL 0.83% 705.25k 16.25m
22 IHLEN HELENE KRISTINE 0.76% 645.63k 14.88m
23 WL-01 HOLDING AS 0.72% 607.6k 14m
24 RESULTING AS 0.67% 571.5k 13.17m
25 S FJORD INVEST AS 0.51% 434k 10m
26 JONASSEN ULF EUGEN 0.51% 431.18k 9 935k
27 HARSTAD JOHAN CHRISTIAN 0.51% 429.66k 9 900k
28 SONJA OG EMIL AUBERTS LEGAT STI 0.48% 404.02k 9 309k
29 BØRSELIEN HELGE STEINAR 0.47% 394.94k 9 100k
30 ROKINA ALENA 0.40% 342.86k 7 900k
31 AVANZA BANK AB MEGLERKONTO 0.40% 339.85k 7 831k ++++21 335
32 HANDELAND ØYVIND 0.38% 325.5k 7 500k
33 FAGERBAKKE JOHN TERJE 0.36% 303.8k 7 000k
34 INNSELSET-SMIDTSRØD SANDER 0.36% 301.15k 6 939k
35 RUTEN AS 0.33% 275.76k 6 354k
36 STORM-JOHANNESSEN PÅL 0.32% 273.69k 6 306k
37 AASHEIM STEINAR 0.31% 260.4k 6 000k
38 GEHITO AS 0.31% 260.4k 6 000k +++++1 986k
39 ZAPFFE AUDUN 0.29% 248.97k 5 737k
40 LITLESKARE KENNETH 0.28% 238.7k 5 500k
41 HOVIND SVENN IDAR FORBERGSKOG 0.26% 221.24k 5 098k
42 NILSEN SIMEN NESTOR 0.26% 217k 5 000k
43 KJELSRUD JOHN-EGIL 0.23% 192.01k 4 424k
44 ADVOKATFIRMA SYVERTSEN AS 0.22% 187.47k 4 320k
45 NORDEA BANK ABP 0.21% 174.44k 4 019k
46 RWL HOLDING AS 0.20% 173.6k 4 000k
47 WIK LEIF MAGNE 0.19% 162.75k 3 750k
48 ALI AHMED HARUUN 0.18% 156.05k 3 596k
49 HASSELEID WRÅL MAGNE 0.18% 152.43k 3 512k ++++36 000
50 PERFORMAX AS 0.17% 141.8k 3 267k
TOP50 , det holdes på aksjene etter at flere har økt kraftig siste uken. The potential is so huge, no one above and no one next to it. Stay tuned because big things are happening soon 《 Proof of consept》. Almås øker ikke med 115 millioner aksjer på gøy.
Oversikt for SOFTX (SOFTOX SOLUTIONS ). Oppdatert VPS 7.04.2025
01 PRO AS 13.61% 11.52m 265.6m
02 ALMHAUG BOLIG AS 9.95% 8 426.1k 194.2m
03 OSLO NÆRINGSUTVIKLING AS 8.13% 6 886.2k 158.7m
04 J G INVEST AS 4.84% 4 098.2k 94.43m
05 HAREFRØKEN INVEST AS 4.80% 4 063.5k 93.63m
06 BONICA AS 4.37% 3 696.7k 85.18m
07 NORDNET LIVSFORSIKRING AS 2.87% 2 432.3k 56.04m -565.2k
08 DANSKE BANK A/S 2.54% 2 150.4k 49.55m
09 STIFTELSEN UNI 2.44% 2 068.2k 47.66m
10 LOYD AS 2.12% 1 792.5k 41.3m
11 NORDNET BANK AB 1.97% 1 668.6k 38.45m ++++1 226k
12 AUBERT INVEST AS 1.89% 1 604.3k 36.97m
13 ALMÅS INGEBORG VICTORIA AARSVOLD 1.83% 1 549.2k 35.7m
14 WL-02 HOLDING AS 1.57% 1 330.5k 30.66m
15 HOLTA & CO. AS 1.45% 1 224.4k 28.21m
16 GH HOLDING AS 1.30% 1 099k 25.32m
17 GEMALLO AS 1.28% 1 084.3k 24.98m
18 ARJO BYGG AS 0.90% 759.5k 17.5m
19 BØRSELIEN MARIUS 0.89% 752.02k 17.33m
20 THE BANK OF NEW YORK MELLON SA/NV 0.85% 716.79k 16.52m
21 RONGVED PÅL 0.83% 705.25k 16.25m
22 IHLEN HELENE KRISTINE 0.76% 645.63k 14.88m
23 WL-01 HOLDING AS 0.72% 607.6k 14m
24 RESULTING AS 0.67% 571.5k 13.17m
25 S FJORD INVEST AS 0.51% 434k 10m
26 JONASSEN ULF EUGEN 0.51% 431.18k 9 935k
27 HARSTAD JOHAN CHRISTIAN 0.51% 429.66k 9 900k
28 SONJA OG EMIL AUBERTS LEGAT STI 0.48% 404.02k 9 309k
29 BØRSELIEN HELGE STEINAR 0.47% 394.94k 9 100k
30 ROKINA ALENA 0.40% 342.86k 7 900k
31 AVANZA BANK AB MEGLERKONTO 0.40% 339.85k 7 831k ++++21 335
32 HANDELAND ØYVIND 0.38% 325.5k 7 500k
33 FAGERBAKKE JOHN TERJE 0.36% 303.8k 7 000k
34 INNSELSET-SMIDTSRØD SANDER 0.36% 301.15k 6 939k
35 RUTEN AS 0.33% 275.76k 6 354k
36 STORM-JOHANNESSEN PÅL 0.32% 273.69k 6 306k
37 AASHEIM STEINAR 0.31% 260.4k 6 000k
38 GEHITO AS 0.31% 260.4k 6 000k +++++1 986k
39 ZAPFFE AUDUN 0.29% 248.97k 5 737k
40 LITLESKARE KENNETH 0.28% 238.7k 5 500k
41 HOVIND SVENN IDAR FORBERGSKOG 0.26% 221.24k 5 098k
42 NILSEN SIMEN NESTOR 0.26% 217k 5 000k
43 KJELSRUD JOHN-EGIL 0.23% 192.01k 4 424k
44 ADVOKATFIRMA SYVERTSEN AS 0.22% 187.47k 4 320k
45 NORDEA BANK ABP 0.21% 174.44k 4 019k
46 RWL HOLDING AS 0.20% 173.6k 4 000k
47 WIK LEIF MAGNE 0.19% 162.75k 3 750k
48 ALI AHMED HARUUN 0.18% 156.05k 3 596k
49 HASSELEID WRÅL MAGNE 0.18% 152.43k 3 512k ++++36 000
50 PERFORMAX AS 0.17% 141.8k 3 267k
Christian-DK
07.04.2025 kl 17:19
5918
Hvor henter du oplysninger på top50 ?
På selskabets hjemmeside kan man jo ikke se disse oplysninger - kun top10 så vidt jeg husker.
På selskabets hjemmeside kan man jo ikke se disse oplysninger - kun top10 så vidt jeg husker.
Rekyl
07.04.2025 kl 21:32
5577
Veldig spennende nå.. steg mye på slutten idag med et par feite kjøp. Bygger momentum nå novo guttene
Christian-DK
07.04.2025 kl 21:35
5565
Er der nogen, som har set tegn på, at NOVO kan være interesseret i selskabet?
Rekyl
07.04.2025 kl 22:04
5500
Det er en tydelig link der ja.. hvordan tolker dere kjøpet på 115 millioner aksjer av Kristian Almås…?
Rekyl
08.04.2025 kl 10:03
5042
Soft ox er interessant av flere grunner - men også fordi denne typen aksjer er bra aksjer i tider hvor markedet opplever svingninger- da er helse aksjer typ soft ox spennende.
Vangen
09.04.2025 kl 13:33
4687
Hei Stjerna! Er du og Gullhaugen en og samme person? I alle fall like artig å lese de kraftfulle innleggene dine som det Gullet kommer med. Når det gjelder aksjen, så ser det ikke så lystig ut i dag - som med resten av børsen. Da er det godt at du i alle fall er ultrapositiv og gir oss andre håp 🙏
Redigert 09.04.2025 kl 16:16
Du må logge inn for å svare
Rekyl
09.04.2025 kl 15:04
4532
Jo mere man leser jo om soft ox desto mer tro
Redigert 09.04.2025 kl 15:05
Du må logge inn for å svare
Star
14.04.2025 kl 08:06
3532
10øre kommer i dag.
Softox den forsvunne diamant
Investornytt av Investornytt
Softox den forsvunne diamant
Investornytt av Investornytt
Redigert 14.04.2025 kl 08:31
Du må logge inn for å svare
Star
14.04.2025 kl 16:06
3033
Billyjojimbob skrev Drahjelp fra investor nytt i dag👍
Ser vi 8 til 10 i morgen?
Gullhaugen
22.04.2025 kl 13:01
2366
US ARMY GOES FOR FDA APPROVAL WITH SOFTOX IN THE USA. WHAT DOES IT MEAN? BIG Biopharma deal
Star
25.04.2025 kl 02:22
2095
Spenningen stiger aksjen kan gå fort opp mot 50 nå, enrom handel i dag.
Star
10.05.2025 kl 07:45
885
SoftOx SolutionsSoftOx Solutions
ABOUT US
A pharmaceutical company
SoftOx Solutions AS (SoftOx, listed at Euronext Growth Oslo) is a clinical-stage pharmaceutical company based in Oslo, Norway. We have developed a non-toxic and highly efficient antimicrobial technology designed to address some of the world’s greatest health challenges, including:
01
Targeting airway infections with endogenous molecule
The SoftOx technology stabilizes an endogenous pan-antimicrobial molecule (HOCl) thereby enhancing one of the immune system’s ways of eradicating pathogens in the airways.
02
Alleviating antimicrobial resistance (AMR) development
As HOCl’s mode of action is unspecific and metabolic independent, no resistance develops when using SoftOx technology. According to the World Health Organization, AMR is a major threat to global health. New forms of resistance are emerging and can spread with remarkable speed between continents. Therefore, the SoftOx technology is likely highly important to counteract this detrimental development.
03
VAP and chronic infections
SoftOx Inhalation Solution (SIS) is effective against pathogens causing VAP as well as other airway infections/pneumonia. With inhaled administration of the nebulized SIS, the treatment will be local, tolerable and is expected to be highly effective.
04
Spread of viruses
Deadly viral outbreaks are expected in the future. There remains an unmet need for effective and well-tolerated virucidal solutions to aid infection prevention and control. SoftOx Inhalation Solution (SIS) has a strong virucidal capacity.
OUR VISION
New ways of eradicating infections
Our vision seemed almost unreachable when SoftOx began work on its formulations 10 years ago. It took plenty of hard work, a strong belief in our research, and a stubbornness to overcome uncertainties, setbacks, and other challenges, and get to where we are today. Thanks to the dedication and commitment of our team, and to the core values we all share, SoftOx is currently in a prime position.
As SoftOx develops into a well-known brand, we will learn to navigate various obstacles. It is therefore important to emphasize that our long-term goals are now within reach, and our ongoing research and development have resulted in greater confidence and optimism than ever before.
Charles Alexandre de Calonne once said: “Nothing is impossible, the impossible just takes a little longer”. This statement corresponds well with our dedication to developing solutions serving human health.
WE ARE COLLABORATING WITH
Leading Research Institutions & Organisations
After years of research and product development
In collaboration With leading Nordic research institutes
SoftOx has developed a non-toxic and highly effective antimicrobial technology, which eradicates and prevents biofilm infections and is fully virucidal.
SoftOx is all about Technology
The unique SoftOx technology, developed in close collaboration with expert scientists and clinicians from the universities in Skåne County and the University of Copenhagen, is based on a combination of naturally occurring chemicals that harbour broad antimicrobial effects without inducing resistance. There is documentation to confirm that this technology has a strong antimicrobial effect against all bacteria (including MRSA), fungi, and viruses tested. Pre-clinical and clinical trials indicate that SoftOx technology is well tolerated. Given its favorable benefit-risk profile, SoftOx technology aims to raise the standards for disinfectants and wound care products.
Developed With Top Ranked Scientists
Aiming to Solve Major Health Challenges
post-image-five
SoftOx Solutions AS is a pharmaceutical company, founded in 2012. After years of research and product development with leading Nordic research institutions, SoftOx has developed a non-toxic and highly efficient pan-antimicrobial technology, which eradicates bacteria, including bacteria in biofilms, and fungi, and is fully virucidal. This technology is in development as a pan-antimicrobial inhaled solution to combat respiratory infections.
Copyright © 2025 SoftOx Solutions. All rights reserved.
ABOUT US
A pharmaceutical company
SoftOx Solutions AS (SoftOx, listed at Euronext Growth Oslo) is a clinical-stage pharmaceutical company based in Oslo, Norway. We have developed a non-toxic and highly efficient antimicrobial technology designed to address some of the world’s greatest health challenges, including:
01
Targeting airway infections with endogenous molecule
The SoftOx technology stabilizes an endogenous pan-antimicrobial molecule (HOCl) thereby enhancing one of the immune system’s ways of eradicating pathogens in the airways.
02
Alleviating antimicrobial resistance (AMR) development
As HOCl’s mode of action is unspecific and metabolic independent, no resistance develops when using SoftOx technology. According to the World Health Organization, AMR is a major threat to global health. New forms of resistance are emerging and can spread with remarkable speed between continents. Therefore, the SoftOx technology is likely highly important to counteract this detrimental development.
03
VAP and chronic infections
SoftOx Inhalation Solution (SIS) is effective against pathogens causing VAP as well as other airway infections/pneumonia. With inhaled administration of the nebulized SIS, the treatment will be local, tolerable and is expected to be highly effective.
04
Spread of viruses
Deadly viral outbreaks are expected in the future. There remains an unmet need for effective and well-tolerated virucidal solutions to aid infection prevention and control. SoftOx Inhalation Solution (SIS) has a strong virucidal capacity.
OUR VISION
New ways of eradicating infections
Our vision seemed almost unreachable when SoftOx began work on its formulations 10 years ago. It took plenty of hard work, a strong belief in our research, and a stubbornness to overcome uncertainties, setbacks, and other challenges, and get to where we are today. Thanks to the dedication and commitment of our team, and to the core values we all share, SoftOx is currently in a prime position.
As SoftOx develops into a well-known brand, we will learn to navigate various obstacles. It is therefore important to emphasize that our long-term goals are now within reach, and our ongoing research and development have resulted in greater confidence and optimism than ever before.
Charles Alexandre de Calonne once said: “Nothing is impossible, the impossible just takes a little longer”. This statement corresponds well with our dedication to developing solutions serving human health.
WE ARE COLLABORATING WITH
Leading Research Institutions & Organisations
After years of research and product development
In collaboration With leading Nordic research institutes
SoftOx has developed a non-toxic and highly effective antimicrobial technology, which eradicates and prevents biofilm infections and is fully virucidal.
SoftOx is all about Technology
The unique SoftOx technology, developed in close collaboration with expert scientists and clinicians from the universities in Skåne County and the University of Copenhagen, is based on a combination of naturally occurring chemicals that harbour broad antimicrobial effects without inducing resistance. There is documentation to confirm that this technology has a strong antimicrobial effect against all bacteria (including MRSA), fungi, and viruses tested. Pre-clinical and clinical trials indicate that SoftOx technology is well tolerated. Given its favorable benefit-risk profile, SoftOx technology aims to raise the standards for disinfectants and wound care products.
Developed With Top Ranked Scientists
Aiming to Solve Major Health Challenges
post-image-five
SoftOx Solutions AS is a pharmaceutical company, founded in 2012. After years of research and product development with leading Nordic research institutions, SoftOx has developed a non-toxic and highly efficient pan-antimicrobial technology, which eradicates bacteria, including bacteria in biofilms, and fungi, and is fully virucidal. This technology is in development as a pan-antimicrobial inhaled solution to combat respiratory infections.
Copyright © 2025 SoftOx Solutions. All rights reserved.
Gullhaugen
20.05.2025 kl 08:44
421
20.05.2025 - DANSKE BANK A/S fortsetter økningen. Hvem skjuler seg bak denne kontoen? Novo Nordisk?
01 PRO AS 14.40% 27.69m 322.7m
02 ALMHAUG BOLIG AS 8.67% 16.66m 194.2m
03 OSLO NÆRINGSUTVIKLING AS 6.86% 13.19m 153.7m
04 DANSKE BANK A/S 4.45% 8 553.6k 99.69m +++++191k
05 J G INVEST AS 4.33% 8 320.5k 96.98m
06 BONICA AS 3.80% 7 308.3k 85.18m
07 NORDNET BANK AB 3.63% 6 978.1k 81.33m ++++2 262k
08 THE BANK OF NEW YORK MELLON SA/NV 2.95% 5 665.4k 66.03m
09 HAREFRØKEN INVEST AS 2.73% 5 243k 61.11m
10 NORDNET LIVSFORSIKRING AS 2.54% 4 880.3k 56.88m -3 963k
11 THE BANK OF NEW YORK MELLON SA/NV 2.32% 4 451.2k 51.88m 14
12 AUBERT INVEST AS 2.29% 4 397.4k 51.25m
13 STIFTELSEN UNI 2.13% 4 088.8k 47.66m
14 HOLTA & CO. AS 1.90% 3 646.3k 42.5m
15 S FJORD INVEST AS 1.79% 3 432k 40m
16 LOYD AS 1.72% 3 303.3k 38.5m
17 JONASSEN ULF EUGEN 1.64% 3 143.3k 36.64m
18 ALMÅS INGEBORG VICTORIA AARSVOLD 1.59% 3 062.8k 35.7m
19 WL-02 HOLDING AS 1.23% 2 365k 27.56m
20 GEMALLO AS 1.12% 2 143.6k 24.98m
21 BØRSELIEN MARIUS 0.77% 1 486.7k 17.33m
22 SONJA OG EMIL AUBERTS LEGAT STI 0.73% 1 411.6k 16.45m
23 RONGVED PÅL 0.73% 1 394.3k 16.25m
24 HARSTAD JOHAN CHRISTIAN 0.69% 1 334.8k 15.56m
25 WL-01 HOLDING AS 0.62% 1 201.2k 14m +++++1 157k
26 RESULTING AS 0.59% 1 129.8k 13.17m
27 MINBOD.NO LAGERHOTELL AS 0.56% 1 072.5k 12.5m +++++2 500k
28 IHLEN HELENE KRISTINE 0.53% 1 019k 11.88m
29 ARJO BYGG AS 0.51% 988.42k 11.52m +++++70 000
30 BØRSELIEN HELGE STEINAR 0.41% 780.78k 9 100k
31 AVANZA BANK AB MEGLERKONTO 0.41% 778.7k 9 076k -3 867k
32 ROKINA ALENA 0.35% 677.82k 7 900k
33 INNSELSET-SMIDTSRØD SANDER 0.34% 659.72k 7 689k
34 HANDELAND ØYVIND 0.33% 643.5k 7 500k
35 NILSEN SIMEN NESTOR 0.31% 600.6k 7 000k +++++350k
36 JENSEN CARINA MARIANNE 0.30% 569.01k 6 632k
37 AASHEIM STEINAR 0.27% 514.8k 6 000k
38 GEHITO AS 0.27% 514.8k 6 000k
39 UBS AG LONDON BRANCH 0.27% 513.08k 5 980k +++++181.8k
40 LITLESKARE KENNETH 0.25% 471.9k 5 500k
41 KJELSRUD JOHN-EGIL 0.23% 439.65k 5 124k
42 STORM-JOHANNESSEN PÅL 0.22% 429k 5 000k
43 THE BANK OF NEW YORK MELLON SA/NV 0.21% 395.65k 4 611k +++++306.6k
44 NORDEA BANK ABP 0.19% 364.62k 4 250k +++++50 000
45 MØLLER ULRICH 0.18% 343.2k 4 000k
46 SKJERVE KRISTOFFER 0.18% 341.48k 3 980k INN
47 KAHSAI YONAS GEBRU 0.18% 341.31k 3 978k INN
48 J.P. MORGAN SECURITIES PLC 0.17% 327.65k 3 819k
49 COLLEGIUM MANAGEMENT AS 0.17% 326.23k 3 802k
50 LIU SAI WAH 0.17% 326.04k 3 800k
01 PRO AS 14.40% 27.69m 322.7m
02 ALMHAUG BOLIG AS 8.67% 16.66m 194.2m
03 OSLO NÆRINGSUTVIKLING AS 6.86% 13.19m 153.7m
04 DANSKE BANK A/S 4.45% 8 553.6k 99.69m +++++191k
05 J G INVEST AS 4.33% 8 320.5k 96.98m
06 BONICA AS 3.80% 7 308.3k 85.18m
07 NORDNET BANK AB 3.63% 6 978.1k 81.33m ++++2 262k
08 THE BANK OF NEW YORK MELLON SA/NV 2.95% 5 665.4k 66.03m
09 HAREFRØKEN INVEST AS 2.73% 5 243k 61.11m
10 NORDNET LIVSFORSIKRING AS 2.54% 4 880.3k 56.88m -3 963k
11 THE BANK OF NEW YORK MELLON SA/NV 2.32% 4 451.2k 51.88m 14
12 AUBERT INVEST AS 2.29% 4 397.4k 51.25m
13 STIFTELSEN UNI 2.13% 4 088.8k 47.66m
14 HOLTA & CO. AS 1.90% 3 646.3k 42.5m
15 S FJORD INVEST AS 1.79% 3 432k 40m
16 LOYD AS 1.72% 3 303.3k 38.5m
17 JONASSEN ULF EUGEN 1.64% 3 143.3k 36.64m
18 ALMÅS INGEBORG VICTORIA AARSVOLD 1.59% 3 062.8k 35.7m
19 WL-02 HOLDING AS 1.23% 2 365k 27.56m
20 GEMALLO AS 1.12% 2 143.6k 24.98m
21 BØRSELIEN MARIUS 0.77% 1 486.7k 17.33m
22 SONJA OG EMIL AUBERTS LEGAT STI 0.73% 1 411.6k 16.45m
23 RONGVED PÅL 0.73% 1 394.3k 16.25m
24 HARSTAD JOHAN CHRISTIAN 0.69% 1 334.8k 15.56m
25 WL-01 HOLDING AS 0.62% 1 201.2k 14m +++++1 157k
26 RESULTING AS 0.59% 1 129.8k 13.17m
27 MINBOD.NO LAGERHOTELL AS 0.56% 1 072.5k 12.5m +++++2 500k
28 IHLEN HELENE KRISTINE 0.53% 1 019k 11.88m
29 ARJO BYGG AS 0.51% 988.42k 11.52m +++++70 000
30 BØRSELIEN HELGE STEINAR 0.41% 780.78k 9 100k
31 AVANZA BANK AB MEGLERKONTO 0.41% 778.7k 9 076k -3 867k
32 ROKINA ALENA 0.35% 677.82k 7 900k
33 INNSELSET-SMIDTSRØD SANDER 0.34% 659.72k 7 689k
34 HANDELAND ØYVIND 0.33% 643.5k 7 500k
35 NILSEN SIMEN NESTOR 0.31% 600.6k 7 000k +++++350k
36 JENSEN CARINA MARIANNE 0.30% 569.01k 6 632k
37 AASHEIM STEINAR 0.27% 514.8k 6 000k
38 GEHITO AS 0.27% 514.8k 6 000k
39 UBS AG LONDON BRANCH 0.27% 513.08k 5 980k +++++181.8k
40 LITLESKARE KENNETH 0.25% 471.9k 5 500k
41 KJELSRUD JOHN-EGIL 0.23% 439.65k 5 124k
42 STORM-JOHANNESSEN PÅL 0.22% 429k 5 000k
43 THE BANK OF NEW YORK MELLON SA/NV 0.21% 395.65k 4 611k +++++306.6k
44 NORDEA BANK ABP 0.19% 364.62k 4 250k +++++50 000
45 MØLLER ULRICH 0.18% 343.2k 4 000k
46 SKJERVE KRISTOFFER 0.18% 341.48k 3 980k INN
47 KAHSAI YONAS GEBRU 0.18% 341.31k 3 978k INN
48 J.P. MORGAN SECURITIES PLC 0.17% 327.65k 3 819k
49 COLLEGIUM MANAGEMENT AS 0.17% 326.23k 3 802k
50 LIU SAI WAH 0.17% 326.04k 3 800k
heilo888
20.05.2025 kl 09:28
328
Volumet i går var begredelig noe som kan tyde på at interessen for aksjen er avtagende.